We are excited to attend PBSS: Roadmap to Formulation Development of Monoclonal Antibodies and Related Proteins: From Pre-Clinical to Commercialization. The Pharmaceutical and BioScience Society International (PBSS) is a non-profit organization of scientists, researchers, and professionals working in the life science sector. With chapters in the United States, Canada, and South Korea, their goal is to foster collaboration and provide growth opportunities through educational and professional development events. Join us for this thought-provoking symposium and stop by our table to learn more about Biocytogen’s preclinical products and services.
What is Roadmap to Formulation Development of Monoclonal Antibodies and Related Proteins: From Pre-Clinical to Commercialization?
This PBBS event will kick off with an overview of the development roadmap of monoclonal antibodies and related proteins, delving into the integrated pathway from preclinical phases to full commercialization. Led by experts across pharma and biotech, the sessions will explore high-throughput screening (HTS) strategies, first-in-human (FIH) formulation, risk mitigation, and more. There will be many opportunities for networking during the vendor show and happy hour.
Event Overview
Date: February 10th, 2026
Venue: Dockside at Dukes, 1111 Fairview Ave N, Seattle, WA
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Seattle!
